Because GHK-Cu operates through cumulative signaling rather than peak concentration, researchers commonly build in an escalation: a lower dose in the first half of a cycle, a higher dose in the second half, followed by a deliberate rest period before starting again
The comparison groups should match the new treatment group in average age, gender distribution, diagnosis, level of functioning, and any other potentially confounding variables
Analysis is performed by Freedom Diagnostics, a US-owned and operated laboratory named directly on each certificate and signed by its principal chemist
The Peptide Catalog is not responsible for any adverse effects resulting from the use or misuse of information presented here.
Maximum effect typically plateaus at 6-9 months of consistent application, after which maintenance protocols using reduced frequency or concentration can sustain results following peptide cycling strategies without requiring indefinite peak-intensity treatment as detailed in SeekPeptides protocols
In the United States, the Food and Drug Administration (FDA) has not approved the body protective compound for medical use, meaning it does not meet the agencys safety and efficacy standards